This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AMAG Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

AMAG Pharmaceuticals, Inc. (AMAG)

Morgan Stanley Healthcare Conference

September 10, 2012 11:45 am ET


Bill Heiden - President and CEO

Frank Thomas - Chief Operating Officer


David Friedman - Morgan Stanley


David Friedman - Morgan Stanley

Thanks very much everyone for coming. I think, we'll get started David Friedman, Biotech Analyst. Just before we start, in terms of the disclosures, I think, everyone has been saying the same thing, personal and Morgan Stanley Holdings disclosures are available, so anyway, more saving things.

We have gentlemen from AMAG Pharmaceuticals. On far side, Frank Thomas, Chief Operating Officer. In the near side, Bill Heiden, President and CEO, and we'd love this to be as interactive as possible, so anyone feel free to ask any questions at point, just raise your hand and we'll make sure we try and calling you or not just make some noise and we'll definitely find you, so thanks again for joining us.

Maybe if we can just start for those who aren't familiar or not up-to-date, if you can just give a couple-minute overview of the company, your guys' focus and where you see things headed?

Bill Heiden

Great, so I should also say that in terms of disclaimers we will be making forward-looking statements in our full disclaimers located on our website as well. I have joined AMAG about three months ago, and what I found is the company that has an asset that's best-in-class compound of product called Feraheme, which is for the treatment of IDA and chronic kidney disease, and we have the largest share of voice last couple of quarters. Very, very strong growth in terms of grams per quarter versus quarter a year ago or prior quarter, so we are seeing nice volume growth.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%
TSLA $232.32 -3.92%
YHOO $36.01 -1.42%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs